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Abstract
Background There is an unmet need for specific and
sensitive imaging techniques to assess the efficacy of breast
cancer therapy, particularly Her-2-expressing cancers.
Ultrasonic microbubbles are being developed for use as
diagnostic and therapeutic tools. However, nanobubbles
circulate longer, are smaller, and diffuse into extravascular
tissue to specifically bind target molecules. Here, we
characterize a novel Herceptin-conjugated nanobubble for
use against Her-2-expressing tumors.
Methods Phospholipid-shelled nanobubbles conjugated
with Herceptin (NBs-Her) were fabricated using a thin-film
hydration method and characterized in vitro in breast
cancer cell lines and in vivo in a mouse model.
Results The average size of the unconjugated nanobub-
bles (NBs-Blank) and NBs-Her was 447.1 ± 18.4 and
613.0 ± 25.4 nm, respectively. In cell culture, the NBs-
Her adhered to Her-2-positive cells significantly better than
to Her-2-negative cells (p\ 0.05). In vivo, the peak
intensity and the half-time to washout of the NBs-Her were
significantly greater than those of the NBs-Blank
(p\ 0.05). In addition, contrast-enhanced ultrasound
imaging quality was improved through the use of the NBs-
Her. The nanobubbles were able to penetrate into tumor
tissue to allow extravascular imaging, but did not penetrate
normal skeletal muscle.
Conclusions The Herceptin-conjugated nanobubble had
many properties that made it useful for in vivo imaging,
including longer circulation time and better tumor selec-
tivity. This platform may be able to provide targeted
delivery of therapeutic drugs or genes.
Keywords Contrast-enhanced ultrasound  Herceptin 
Nanobubble  Phospholipid  Breast cancer
Introduction
Approximately, 20–30 % of breast cancer patients are
diagnosed with Her-2-positive breast cancers, which are
associated with resistance to some chemotherapeutic
agents and poor disease-free survival [1–3]. Early diagno-
sis is critical for successful treatment and improved prog-
nosis of Her-2-positive breast cancer. Cytotoxic
chemotherapy remains the mainstay treatment for breast
cancer [4, 5]. More recently, neoadjuvant chemotherapy
was established for breast cancer. These treatments aim to
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increase tumor respectability and allow breast-conserving
therapies [6]. The combination of trastuzumab (also known
as Herceptin), a humanized monoclonal antibody (mAb)
against the Her-2 receptor [7], and neoadjuvant chemo-
therapy has improved the response rate for breast cancers
that overexpress Her-2.
Recent studies have highlighted the importance of
identifying patients who are not responsive to neoadjuvant
chemotherapy early, so that subsequent treatment and
postoperative chemotherapy regimens [8] can be altered to
minimize toxicity and optimize the timing of surgery.
Therefore, a sensitive and specific method to identify the
tumor response to neoadjuvant chemotherapy is required.
Contrast-enhanced ultrasonography (CEUS) is a useful
diagnostic tool to detect the vascular pattern of breast
cancers. It is more sensitive than conventional imaging
modalities, such as mammography and B-mode ultraso-
nography, which is more susceptible to confounding effects
from breast edema and fibrosis, common side effects of
chemotherapy [9]. Ultrasonic molecular imaging could be a
new diagnostic technique for estimating the efficacy of
neoadjuvant chemotherapy in Her-2-positive breast can-
cers. However, in practice, the ultrasound microbubbles
(MBs) currently used for CEUS are limited by their
diameter (1–10 lm), can only produce blood pool contrast
and are rapidly cleared from the cancer tissue, resulting in
short-acting contrast. In addition, ultrasound MBs cannot
be targeted to specific tumor antigens using antibodies or
ligands on the bead surface, because they are unable to
efficiently pass through the submucosal layers into tumor
tissue.
Significant energy has been invested to develop nano-
technology tools for cancer diagnosis and therapy. Ultra-
sound contrast agents using this principle could be
considered ‘‘theranostic,’’ combining therapy and diag-
nostics. They also have the advantage of being naturally
acoustically activated. Unlike MBs, nanobubbles (NBs)
efficiently penetrate through submucosal layers and have
longer circulation times in vivo [10–13]. Rapoport et al.
[14] confirmed that nanoscale particles can penetrate the
tumor neovasculature and tumor tissue space, to achieve
relatively long-acting contrast enhancement. NBs are also
amenable to surface modifications that enhance their signal
and tumor selectivity, and reduce non-specific toxicity.
Targeting NBs through surface modifications is considered
a promising theranostic approach. In preclinical medical
imaging studies, Herceptin and its analogs have been
shown to be effective targeting tools [15–19]. Thus, breast
cancers that overexpress Her-2 are an attractive target for
continued development of specific theranostic approaches.
Moreover, equipping NBs with specific antibodies may be
a simple means of producing specific targeted delivery
systems [20].
In 2007, Liu et al. [20] reported the developments of
polylactic acid (PLA) NBs conjugated with Herceptin,
which showed specific imaging in vitro, but the NBs were
not tested in vivo. Here, we developed a novel Herceptin-
PEGylated phospholipid-shell NB reagent and character-
ized its in vitro and in vivo properties. We then evaluated
the specificity, cytotoxicity, and efficiency of the NBs
against Her-2-positive breast cancer cells.
Materials and methods
Preparing the nanobubbles
Bubbles were prepared using a thin-film hydration and soni-
cation method [21, 22]. Briefly, a homogenous mixture con-
taining 5 mg of 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine (DPPE, Sigma-Aldrich, St. Louis,
Missouri), 15 mg of 1,2-distearoyl-sn-glycero-3-phos-
phocholine (DSPC, Sigma-Aldrich, St. Louis, Missouri),
6.3 mg of polyethylene glycol (PEG4000, Aladdin Limited
Company, Shanghai, China), and 2.2 mg of 2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-carboxy polyethylene
glycol 2000 (DSPE-PEG2000-COOH, Avanti Polar Lipids
Inc., Alabaster, Alabama)wasmade in 4 mL chloroform. The
mixture was stirred for 2 h and then vacuum dried for 1 h at
60 C using a rotary evaporator (EYELA, Tokyo, Japan). The
resulting film was rehydrated with phosphate-buffered saline
(PBS) to a concentration of 5 mg/mL and agitated at 50 C at
120 rpm for 1 h.
The size of the resulting liposomes was reduced by
sonication using a 100-kHz probe (Modal 220A, Branson
Ultrasonics, Danbury) at high power (10 min, 120 W). The
liposomal suspension was transferred to a tube and 5 mL of
octafluoropropane (C3F8; Guangzhou Walter, China) gas
was injected to replace the air over the fluid. Bubbles were
created with additional sonication (30 s, 100 W). The ini-
tial bubbles ranged in size from 100 to 5000 nm and were
purified to bubbles between 200 and 700 nm. First, the
visible bubbles were discarded with a syringe, and a low-
speed centrifugation (1000 rpm, 5 min) was performed to
separate a thin upper layer in the suspension to discard
large bubbles. Then the suspension was transferred to a
5 mL syringe and a higher centrifugation speed (2500 rpm,
15 min) was used. The bottom layer of liquid containing
phospholipid fragments and liposomes was removed; then
the NBs were collected and washed twice in PBS. Finally,
the PEGylated nanobubbles were resuspended in 4 mL
PBS and stored at 4 C.
DiO (Beyotime, Haimen, China)-encapsulated bubbles
were prepared using the same procedure, with the addition
of DiO in the initial mixture of phospholipids and PEG in
chloroform.
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Preparing Herceptin-targeted nanobubbles
Herceptin molecules were covalently bound to the PEGy-
lated NBs (NBs-Blank) by linking the free amino groups of
Herceptin and the carboxyl groups of DSPE-PEG2000 on
the NBs. Briefly, 1-ethyl-3-(dimethylaminopropyl)carbo-
diimide hydrochloride (EDC, Sigma-Aldrich, St. Louis,
Missouri) was mixed with N-hydroxysuccinamide (NHS,
Sigma-Aldrich, St. Louis, Missouri) using an
EDC:NHS:DSPE-PEG2000 molar ratio of 30:30:3 in a
2-(4-morpholino)ethanesulfonic acid (MES, Sigma-
Aldrich, St. Louis, Missouri) solution (pH 5.5) for 30 min
at room temperature. Then, the suspension was removed
and centrifuged (1000 rpm, 5 min) three times to remove
excess EDC and NHS. Herceptin (Hoffman La Roche,
1 mg/mL) was then added with a Herceptin/DSPE-
PEG2000 molar ratio of 1:30 and incubated at 4 C for 8 h
(NBs-Her). Finally, the upper layer of the suspension was
collected and washed (1000 rpm, 5 min) three times to
remove the excess free Herceptin and stored at 4 C.
Determining bubble size and zeta potential
Bubble size and size distribution were measured at 25 C
using photon correlation spectroscopy at a scattering angle
of 90 using a Zetasizer Nano ZS90 (Malvern Instruments,
Worcestershire, UK). Samples were diluted 250-fold in
distilled water to obtain the appropriate viscosity.
Zeta potential values were also obtained using a Zeta
sizer NanoZS90 with an He–Ne laser beam at 633 nm and
a scattering angle of 90 at 25 C. The samples were dis-
persed in distilled water and the zeta potentials were cal-
culated from the mean electrophoresis mobility using the
Smoluchowski equation.
Determining nanobubble concentration
The NBs concentration was determined using a hemocy-
tometer. An NB sample fluorescently labeled with DiO was
transferred to the hemocytometer and observed using a
CarlZeiss Aviox-1 inverted fluorescence microscope (Carl
Zeiss, Oberkirchen, Germany). A fluorescent and bright
field image (4009) was obtained for each field of view
(n = 3). The number of bubbles in each field was counted
using the WCIF Image J software (v1.37; National Insti-
tutes of Health, Bethesda, MA). Sample concentrations
(number/mL) were determined using the same method. All
measurements were performed in triplicate.
Western blot analysis
SDS-PAGE and Western blot were used to confirm whe-
ther Herceptin was bound to the NBs. An 8 % SDS–
polyacrylamide gel was loaded with NBs-Blank, NBs-Her,
and Herceptin and electrophoresed under reducing condi-
tion for 2 h at 60 mV and for an additional 180 min at
300 mA. The gel was then transferred to a membrane and
blocked using 5 % skim milk. After blocking, the mem-
branes were incubated overnight at 4 C with a mouse
antibody against ErbB2 (1:1000 dilution; Abcam, Cam-
bridge, MA). Horseradish peroxidase (HRP)-conjugated
donkey anti-mouse IgG (1:2000 dilution; Santa Cruz Bio-
technology, Santa Cruz, CA) was used as the secondary
antibody. Protein signals were detected using a chemilu-
minescence system (New Life Science Products, Boston,
MA, USA).
Cytotoxicity analysis
SK-BR3 (high Her-2 expression) and MDA-MB-231 (low
Her-2 expression) breast cancer cells were provided by
American Type Culture Collection (ATCC) [23]. The
MDA-MB-231 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, GIBCO Gaithersburg, MD,
USA) with high glucose supplemented with 10 % fetal
bovine serum and at 37 C with 5 % CO2. The SK-BR3
cells were cultured in RPMI 1640 (GIBCO Gaithersburg,
MD) with 10 % fetal bovine serum and at 37 C with 5 %
CO2. SK-BR3 and MDA-MB-231 cells were inoculated
into 96-well plates at 2 9 103 cells/well in 0.1 mL of
medium for 12 h. The cells were then incubated for an
additional 24 h in the same volume of fresh media with
targeted or nonspecific NBs at 0, 2 9 104, 2 9 105,
2 9 106, and 2 9 107 bubbles/mL. After 24 h, the medium
in each well was replaced with 100 lL of fresh medium
containing 10 lL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT; 5 mg/mL) and incubated
for an additional 4 h. Then, 100 lL of DMSO was added to
dissolve the substrate after the MTT-containing superna-
tant was discarded. The plates were gently agitated for
5 min, and the absorbance of each well was determined at
540 nm using an Infinite F200 multimode plate reader
(Spectra Max M5, Molecular Devices). All experiments
were conducted in triplicate. The cell viability was
calculated.
Cell attachment studies
SK-BR3 and MDA-MB-231 cells were grown on cham-
bered coverslips for 24 h. The plates were first washed
three times with PBS to remove the dead cells. The cells
were counterstained with 406-diamidino-2-phenylindole
(DAPI, Beyotime, Haimen, China). The cells were incu-
bated with approximately 5 9 105 DiO-encapsulated NBs-
Her or NBs-Blank for 30 min at room temperature, then
washed three times with PBS to remove the unbound NBs.
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PBS (0.5 mL) was added to each well to differentiate
between bound and unbound NBs, which floated to the
surface. Images were captured with confocal laser scanning
microscopy (CLSM, Zessi LSM 710, Germany). DiO and
DAPI were excited at 484 and 364 nm, and emission was
recorded at 501 and 454 nm, respectively.
To evaluate binding efficiency, cells were cultured on
coverslips in 6-well plates until they reached 70 % con-
fluence. The plates were washed twice with PBS, and
5 9 107 DiO-encapsulated NBs-Her or NBs-Blank were
added. Because the NBs are buoyant, the coverslips were
inverted to facilitate contact between the cells and bubbles
at room temperature. After 30 min, the coverslips were
washed with PBS to remove unbound NBs. Finally, the
cells were washed to the bottom of the plate and the
supernatant was removed by centrifugation. The fluores-
cence intensity in the SK-BR-3 and MDA-MB-231 cells
was analyzed by flow cytometry (Beckman Coulter, Ful-
lerton, CA).
In vivo tumor model and contrast-enhanced imaging
All animal experiments were carried out in accordance
with the procedures and guidelines of the Institutional
Animal Care and Use Committee and were approved by the
Animal Experiment Committee and Biosafety Committee
at Sun Yat-Sen University of Medical Science. Approxi-
mately, 3 9 106 MDA-MB-231 or 6–8 9 106 SK-BR3
Table 1 Physicochemical characteristics of NBs
Formation Size (nm) PDI Zeta potential (mV) Concentration (/ml)
NBs 447.1 ± 18.4 0.211 ± 0.022 -38.36 ± 0.81 (1.22 ± 0.16) 9 109
Targeted NBs 613.0 ± 25.4 0.241 ± 0.045 -30.02 ± 0.42 (5.64 ± 0.19) 9 108
Data represent mean ± SD (n = 5)
NBs nanobubbles, PDI particle dispersion index
Fig. 1 In vitro characterization of the Herceptin-conjugated nano-
bubbles. a Western blot analysis of the Herceptin-conjugated
nanobubbles (NBs-Her) using an 8 % native polyacrylamide gel.
Lane 1 unconjugated nanonbubbles (NBs-Blank); lane 2 Herceptin;
lane 3 NBs-Her. b SK-BR-3 and MDA-MB-231 cells were incubated
with NBs-Blank for 24 and 48 h. There were no significant
differences in the viability of SK-BR-3 or MDA-MB-231 cells
cultured with NBs-Blank. c In vitro cytotoxicity assays using Her-2
positive SK-BR-3 cells (high Her-2 expression) and MDA-MB-231
cells (Her-2 negative) incubated with NBs-Her for 24 h. The viability
of SK-BR-3 cells is significantly reduced by exposure to NBs-Her at
high concentrations (p\ 0.05). The stars indicate significant differ-
ences (p\ 0.05). Cell viability data are expressed as mean ± SD
(n = 3)
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cells were inoculated subcutaneously in the second fat pad
of female nude mice (n = 8/group), half of which received
NBs-Her and the other half NBs-Blank. The tumors were
allowed to grow for 2 weeks before ultrasound imaging or
tissue harvest. The mean maximum tumor size at ultra-
sound ranged from 5 to 9 mm. Mice were anesthetized with
2 % chloral hydrate by intraperitoneal injection and placed
on a warm pad. The ultrasound contrast parameters were:
probe frequency, 5–12 MHz; mechanical index (MI), 0.1;
and gain 85 %. (PHILIPS, IU22 MATRIX). A B-mode
image of the tumor was obtained first and used as an
anatomical reference for quantification. Approximately,
1 9 108 NBs-Blank (n = 4/group) or 1 9 108 NBs-Her
(n = 4/group) were injected through caudal veins in MDA-
Fig. 2 Nanobubbles adherence to tumor cells in vitro. The same
quantity of Herceptin-conjugated nanobubbles (NBs-Her) and uncon-
jugated nanobubbles (NBs-Blank) were added to SK-BR3 and MDA-
MB-231 breast cancer cells and then observed using confocal laser
scanning microscopy. a SK-BR-3 cells with NBs-Blank, bMDA-MB-
231 cells with NBs-Her, c MDA-MB-231 with NBs-Blank, and d SK-
BR-3 cells with NBs-Her. NBs-Blank did not adhere to either SK-
BR3 or MDA-MB-231 cells (a, c), NBs-Her adhered to the SK-BR3
cells (d), but not MDA-MB-231 cells (b) (9200)
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MB-231 or SK-BR3 tumor-bearing mice. Ultrasound con-
trast data were quantified with PHILIPS QLab8.1 software.
Confirming NB tumor penetration
CLSM was used to confirm that the NBs passed through the
inter-endothelial gaps in the tumors. The location of green-
fluorescently dyed NBs was determined in vivo. SK-BR3
tumor-bearing mice were randomly separated into two
groups to receive either NBs-Her or NBs-Bank. Approxi-
mately, 1 9 108 DiO-labeled NBs were injected into the
caudal veins. To clear the labeled bubbles from circulation,
the heart was perfused with 0.9 % normal saline 3 h after
bubble injection. The tumors and muscles of the right thigh
(used as negative controls) were immediately extracted for
sectioning into 5-lm slices. Frozen sections were stained in
a solution of 2 lg/mL DAPI for 10 min to mark the
nucleus. Images were recorded using laser scanning con-
focal microscope (LSCM, Zessi LSM 710, Germany).
Statistical analysis
Count data were expressed as mean ± standard deviation.
Data were compared using paired-sample t tests or uni-
variate analysis of variance as appropriate. All statistical
analyses were performed using SPSS software (Version 19;
SPSS Inc. Chicago, IL, USA). P\ 0.05 was considered to
be significant.
Results
Characterization of the nanobubbles
The physical properties of the NBs are summarized in
Table 1. The average diameter of NBs-Blank and NBs-Her
was (447.1 ± 18.4) nm and (613.0 ± 25.4) nm, respec-
tively. Zeta potential measurements showed that NBs-
Blank had a net negative charge of -38.36 ± 0.81 mV
(n = 5), while the charge of NBs-Her was -
30 ± 0.42 mV (n = 5). The concentrations of NBs-Blank
and NBs-Her were (1.22 ± 0.16) 9 109 bubbles/mL
(n = 5) and (5.64 ± 0.19) 9 108 bubbles/mL (n = 5),
respectively.
Herceptin-binding efficiency to the NBs
Western blot showed that the NBs-Her band was at
approximately the same position as Herceptin (Fig. 1a: lane
3 versus 2), indicating that Herceptin was conjugated with
the PEGylated NBs. Additionally, approximately 53.6 ±
0.43 lg of Herceptin was detected per 1 9 108 NBs using a
BCA protein assay. The deduced coupling efficiency is
approximately 50 %, demonstrating that Herceptin was
efficiently conjugated to the PEGylated NBs.
Assessing the cytotoxicity of NBs against tumor cells
The cytotoxicity of NBs-Blank and NBs-Her was evaluated
using SK-BR3 and MDA-MB-231 cancer cells incubated
Fig. 3 Assessing the binding
efficiency of nanobubbles to
tumor cells by flow cytometry.




(NBs-Blank) bound to MDA-
MB-231 (Her-2 negative) and
SK-BR-3 (Her-2 positive) breast
cancer cells was assessed. The
percentage of cells binding to
the NBs is shown. The
adherence of the NBs-Her was
significantly higher in SK-BR-3
cells than the MDA-MB-231
cells (*p\ 0.05). Data are
reported as mean ± SD (n = 3)
Table 2 Two indicators (mean ± SD) of blank and targeted NBs in
two types of transplanted tumors
Tumor Bubble PI t (dB) HT (min)
SK-BR3 Targeted NBs 19.46 ± 2.29 31.09 ± 2.85
Blank NBs 17.37 ± 1.74 24.02 ± 5.03
MDA-MB-231 Targeted NBs 16.53 ± 1.21 25.09 ± 3.87
blank NBs 16.42 ± 1.01 23.45 ± 3.26
PI peak intensity, HT half-time to washout
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with NBs at four concentrations between 107 and 104/mL for
24 h (Fig. 1b, c). For the SK-BR-3 cells incubated with
NBs-Blank incubated at 2 9 107, 2 9 106, 2 9 105, and
2 9 104/mL concentration after 24 h, the cell viability was
measured to be 87.62 ± 2.59, 88.62 ± 1.49, 91.31 ± 1.91,
and 92.36 ± 0.38 %. There were no significant differences
in the viability of SK-BR3 cells cultured with NBs-Blank.
The SK-BR-3 viability with the NBs-Her was 80.41 ± 2.91,
88.04 ± 3.38, 92.24 ± 1.16, and 92.89 ± 1.08 %. At
higher concentrations (2 9 107 NBs-Her/mL), the mortality
rate of the SK-BR-3 cells was significantly increased
(p\ 0.05). However, given that the NBs-Blank was not
toxic, the cytotoxicity was likely due to the antitumor effect
of Herceptin. Similarly, 88.63 ± 1.03, 91.72 ± 4.74,
93.82 ± 7.75, and 92.23 ± 1.67 % MDA-MB-231 cells
incubated with NBs-Her were viable. The cell viability of
MDA-MB-231 cells incubated with NBs-Blank was
91.64 ± 4.51, 91.11 ± 1.01, 91.66 ± 0.91, and
93.21 ± 1.26 %, respectively. There were no significant
differences in the viability of MDA-MB-231 cells cultured
with NBs-Her or NBs-Blank. The cell viability of both SK-
BR3 and MDA-MB-231 cells remained[80 % after incu-
bation with either type of NBs, indicating they were mini-
mally cytotoxic.
Attachment of NB to tumor cells
Microscopically, the NBs-Her and NBs-Blank bubbles
interacted with the SK-BR-3 and MDA-MB-231 cells in
very different ways. There were most targeted NBs
bound to the SK-BR3 cell membrane than the other
three groups (Fig. 2). Flow cytometric analysis showed
that the NBs-Blank did not attach to the SK-BR-3 and
MDA-MB-231 cells (Fig. 3). NBs-Her also adhered to
MDA-MB-231 cells at very low levels, but adhered at
significantly higher levels to the SK-BR-3 cells (Fig. 3).
In fact, the NBs-Her adhered to SK-BR3 cells approxi-
mately 10 times better than the NBs-Blank (p\ 0.05).
We did not observe any internalization of the NBs by
the tumor cells.
Fig. 4 Time–intensity curve of contrast enhancement in tumors after
injection of unconjugated (NBs-Blank) or Herceptin conjugated
nanobubbles (NBs-Her). a Contrast agent images were acquired at
peak intensity in mice with SK-BR-3 or MDA-MB-231 tumors
(n = 4/group). b, c The peak intensity and half-time to washout of
NBs-Her is shown. Both were obviously greater in mice with SK-BR-
3 tumors treated with NBs-Her than SK-BR3-bearing mice injected
with NBs-Blank or MDA-MB-231-bearing mice injected with NBs-
Her (*p\ 0.05). Data are shown in Table 2
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Stability and ultrasound sensitivity of the targeted NBs
in vivo
The NBs-Her were tested in vivo in tumor-bearing mice
that had been inoculated with either MDA-MB-231 cells
(n = 8) or SK-BR-3 cells (n = 8). In the 16 mice from
both groups, under the same ultrasound conditions, NBs-
Her did not result in any recognizable symptoms of tox-
icity, and none of the animals exhibited apparent signs of
distress after examination. The peak intensity, half-life of
washout, and duration of contrast enhancement were
compared between NBs-Blank and NBs-Her in MDA-MB-
231 and SK-BR-3 tumors (Table 2). In the transplanted
MDA-MB-231 tumors (low Her-2 expression), the peak
intensity of NBs-Her (Fig. 4a) and NBs-Blank (Fig. 4a)
was not significantly different (p = 0.886). Similarly, there
was no significant difference in the half-time to washout
between NBs-Her and NBs-Blank in the MDA-MB-231
model (Fig. 4b, p = 0.578). In contrast, in the transplanted
SK-BR-3 tumors (high Her-2 expression), the peak inten-
sity (Fig. 4a, p = 0.021) and the half-time to washout
(Fig. 4b, p = 0.023) were significantly different between
NBs-Her and NBs-Blank.
Contrast-enhanced images of the tumors continuously
exposed to ultrasound were taken at 0, 1, 30, and 40 min
(Fig. 5a–d). As shown in Fig. 5c, even after 40 min, the
NBs-Her reagent still efficiently enhanced the contrast in
transplanted SK-BR3 tumors, implying it has a longer
duration of action in vivo in the SK-BR-3 tumors than in
the other groups. The mice with SK-BR-3 tumors had a
significantly higher peak intensity (p = 0.03) and half-time
to washout (p = 0.045) than the mice with MDA-MB-231
tumors when they were treated with NBs-Her (Fig. 4a, b).
Assessing NB tumor penetration
Penetration of the NBs into the tumor was assessed using
CLSM. The distribution of the DiO-labeled NBs-Her and
NBs-Blanks were assessed in frozen sections of tumor and
skeletal muscle (Fig. 6). In the transplanted MDA-MB-231
and SK-BR3 tumors, a considerable number of DiO-
labeled NBs-Her (Fig. 6a) or NBs-Blank (Fig. 6b) were
present in the intercellular space. In contrast, there were
very few NBs in the skeletal muscle sections (Fig. 6c, d).
Discussion
Herceptin has proven to be a useful reagent for both
diagnostic and therapeutic strategies targeting Her-2
expression breast cancers [23]. Here, we have developed a
novel Herceptin-conjugated NBs that is a putative thera-
nostic strategy. The NBs-Her provide long-acting contrast
enhancement, are non-toxic in vitro and in vivo, and spe-
cifically bind to tumor cells in vitro. Importantly, they also
efficiently penetrate tumor tissue in vivo and are retained
longer in tumors with high Her-2 expression, suggesting an
interaction between the NBs-Her and Her-2.
Fig. 5 In vivo tumor targeting. Images were taken at the indicated
time points (0, 1, 30, and 40 min) after nanobubbles were injected
into the transplanted SK-BR-3 tumors injected with Herceptin-
conjugated nanobubbles (NBs-Her; a) or unconjugated nanobubbles
(NBs-Blank; b) and in the transplanted MDA-MB-231 tumors
injected with NBs-Her (c) or NBs-Blank (d)
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One key innovation in the NBs-Her reagent is the use of
DSPE-PEG2000-COOH as a linker lipid rather than the
traditional streptavidin/biotin conjugation method [24].
The streptavidin/biotin system has not been widely used for
clinical applications, because biotin–protein bonds may
lead to immunogenicity [25–28]. Instead, we used carbo-
diimide-mediated chemistry to target the NBs using the
DSPE-PEG2000-COOH linker. The binding rate between
Herceptin and the NBs was efficient. In vitro, a signifi-
cantly larger number of mAb-modified NBs-Her adhered to
the SK-BR3 (high Her-2) cells than to the MDA-MB-231
cells (low Her-2), suggesting that the adhesion of NBs to
Her-2-positive breast cancer cells is due to the antigen–
antibody reaction. This confirmed that NBs-Her could be
efficiently targeted. In vitro cytotoxicity testing also
showed that NBs-Her and unconjugated NBs were non-
toxic at concentrations up to 107 bubbles/mL. Slightly
increased cell mortality was observed in the SK-BR3 cells
than the MDA-MB-231 cells, which is likely attributable to
the antitumor activity of Herceptin. Therefore, the low
cytotoxicity of NBs-Her suggests it could be a promising
reagent for tumor imaging.
We tested the imaging capabilities of NBs-Her in vivo
in mice inoculated with either SK-BR-3 or MDA-MB-231
tumor cells. Due to the negative correlation between bub-
ble size and acoustic backscatter intensity, smaller gas-
filled particles, like NBs, were predicted to be difficult to
detect by ultrasound [29]. However, Yin et al. confirmed in
Fig. 6 Tumor penetration by nanobubbles. Representative confocal
laser scanning microscopy images of frozen sections after nuclear
labeling are shown. A large number of DiO-labeled Herceptin-
conjugated and unconjugated nanobubbles were observed in the
tumor intercellular space (a, b), but DiO-labeled targeted and blank
nanobubbles were difficult to detect in skeletal muscle (c, d)
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a mouse model that NBs were able to produce strong
contrast enhancement that persisted for more than an hour,
while the enhanced contrast signal provided by MBs
decayed significantly after 15 min. Similarly, we observed
enhanced contrast for more than 40 min at an ultrasound
frequency of 5–12 MHz, achieving optimal echogenicity
intensities. This could be because the NBs passed through
the endothelial gaps in the tumor in greater numbers, were
retained in the tumor tissue for longer, and aggregated into
micron-sized clusters in the extravascular space [14].
The parameters peak intensity and half-time to washout
may be used as indicators of successful targeting for NB-
enhanced imaging. In the SK-BR-3 model, which expres-
sed high levels of Her-2, the peak intensity and half-time to
washout of NBs-Her were significantly higher than NBs-
Blank. However, in the MDA-MB-231 model, which had
low levels of Her-2 expression, the peak intensity and half-
time to washout were not significantly different between
the two types of NBs. The extended retention time in the
SK-BR-3 model is likely due to the increased number of
interactions between antigen and antibody in the trans-
planted SK-BR3 tumors. Our results are similar to those
published by Wang et al. [30].
CLSM imaging was used to determine if the NBs pen-
etrated through inter-endothelial gaps in the tumors. The
lack of a basement membrane and smooth muscle and the
expansion of the intercellular space in cancer vasculature
result in a maximum pore size of approximately
380–780 nm [28]. This is ample space for NBs with a
diameter\700 nm to pass through the tumor neovascula-
ture to allow extravascular imaging. CLSM imaging was
used to investigate penetration and accumulation of DiO-
labeled NBs in tumors. DiO labeled the tumors with green
fluorescence for imaging. We did not observe significant
differences in tumor penetration between NBs-Her and
NBs-Blank in the SK-BR3-transplanted mice. This could
be because multiple DiO-labeled NBs-Her or NBs-Blank
penetrated the inter-endothelial gaps and were retained in
the tumor for a long time more than an hour. Another
possibility is that the fluorescence was quenched during the
preparation of the frozen sections, while DiO-labeled NBs
fluoresces green in tumor cells in vivo. We did observe a
significant difference in the fluorescence of the tumors and
the frozen thigh sections, likely due to the inability of NBs
to pass through the inter-endothelial gaps of normal tissue.
Our study had some limitations. In vitro, the ability of
NBs to attach to tumor cells was not assessed under flow
conditions that would simulate in vivo exposure of the NBs
to shear stress, which may impact the number of NBs
attached to cells. In addition, future NB attachment studies
in vitro can directly compare NB binding with Her-2
density by using cell lines with different levels of receptor
expression. In vivo, our studies were limited by the rela-
tively small number of animals.
Conclusion
In conclusion, noninvasive and inexpensive sonography
combined with Herceptin-targeted NBs may be a promis-
ing tool for diagnosing and evaluating the treatment
response of Her-2-positive breast cancer. Furthermore,
Herceptin-targeted NBs may also provide a targeted ther-
apy platform if they are coated with chemotherapeutic
drugs or genes. Therefore, the Herceptin-targeted NBs
described here may be a multifunctional tool with prom-
ising clinical applications.
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